Zendal logo

ContactoAccionistas
ES / EN
Zendal LinkedinZendal YoutubeZendal Twitter
GrupoEmpresasNuestra actividadPremiosPersonasPrensa
  • Zendal
    • El Grupo Zendal
    • Isabel Zendal
    • One Health
    • Conocimiento
  • Empresas
    • CZ Vaccines
    • Biofabri
    • Vetia
    • Petia
    • Zinereo
    • Probisearch
    • Laboratorios Ovejero
    • Laboratorios Maymó
    • Zendal Portugal
  • Salud
    • Biofarmacéuticos
    • Salud humana
    • Salud animal
  • Premios Zendal
  • Talento
  • Prensa
  • Contacto
  • Accionistas
  • English
  • Zendal Linkedin
  • Zendal Youtube
  • Zendal Twitter
El Grupo Zendal
Isabel Zendal
One Health
Conocimiento
CZ Vaccines
Biofabri
Vetia
Petia
Zinereo
Probisearch
Zendal Portugal
Biofarmacéuticos
Salud humana
Salud animal
Empleo
Movimiento Z
NOTICIA
18 · 03 · 2025
ZENDAL receives EMA recommendation for its vaccine against EHD
Contacto de prensa
  • Teléfono (+34) 986 330 400
  • b.diaz@zendal.com
18 · 03 · 2025ZENDAL receives EMA recommendation for its vaccine against EHD
LEER MÁS
27 · 02 · 2025Biofabri and IAVI announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC
LEER MÁS
21 · 01 · 2025Zendal supplied 42 million doses of bluetongue vaccine in Europe during 2024.
LEER MÁS
12 · 11 · 2024The Zendal Group Honors Human and Animal Health Innovators at its Fifth Annual Awards Gala
LEER MÁS
24 · 10 · 2024Early detection of Alzheimer’s disease and the development of vaccines against ticks in cattle are the objectives of the projects that won the Zendal Prize.
LEER MÁS
05 · 07 · 2024Zendal launches first vaccine against Epizootic Haemorrhagic Disease (EHD) in Spain
LEER MÁS
28 · 06 · 2024Zendal Group launches the 5th edition of its International Zendal Awards for human and animal health projects
LEER MÁS
20 · 06 · 2024Biofabri and TBVI sign a contract with the European Health and Digital Executive Agency to accelerate the final development of the new TB vaccine MTBVAC
LEER MÁS
23 · 03 · 2024MTBVAC, the first vaccine against Tuberculosis derived from a human source, begins clinical trials in adults in India.
LEER MÁS
18 · 03 · 2024ZENDAL launches the first DNA technology vaccine against canine leishmaniasis
LEER MÁS
24 · 01 · 2024VETIA ANIMAL HEALTH STRENGTHENS ITS PORTFOLIO
LEER MÁS
19 · 12 · 2023IAVI and Zendal announce funding for efficacy trial of promising TB vaccine candidate in Africa
LEER MÁS
  • 1
  • 2
  • 3
Logo Cz VaccinesLogo BiofabriLogo VetiaLogo PetiaLogo ProbiSearchLogo ZinereoLogo OvejeroLogo Maymo
Logo Cz Vaccines
Logo Biofabri
Logo Vetia
Logo Petia
Logo ProbiSearch
Logo Zinereo
Logo Ovejero
Logo Maymo
A Relva s/n. 36410, O Porriño. Pontevedra (Spain)
+34 986 330 400
Zendal LinkedinZendal YoutubeZendal Twitter
BiotecnologíaSalud humanaSalud animalPrensaContactoAviso legalPolítica de privacidadPolítica de cookiesSeguridad ambiental